A recent study carried out by a research team from the Paul-Ehrlich-Institut investigated the immunomodulating properties of ...

Home > Press release: Research: β-Glucans Promising Adjuvants ...

This important study provides solid evidence to support the anti-tumor potential of citalopram, originally an anti-depression drug, in hepatocellular carcinoma (HCC). In addition to their previous ...

Immune cells called regulatory T cells have long been known for their role in countering inflammation. In the setting of ...

Induces potent and long-lasting immune responses to defined antigens or whole pathogens (particles), mainly through the ...

Clinicians may one day be able to treat immune checkpoint inhibitor-related myocarditis without disrupting cancer therapy, findings from a cellular investigation showed.Individuals who die of immune ...

A research team has investigated a new combination therapy against cancer. This therapy employs systemic administration of the tissue hormone interferon-I combined with local application of Imiquimod.

A research team at the Medical University of Vienna led by Maria Sibilia has investigated a new combination therapy against cancer. This therapy ...

Researchers at MedUni Vienna have developed a combination therapy using systemic interferon-I and topical imiquimod.

Researchers believe the innovative idea holds immense promise for tackling a wide range of diseases including cancer through ...

This work could advance the understanding of immune system responses and pave the way for improved vaccines and immunotherapies ...